Intex Pharma Retatrutide 2mg

What is Intex Pharma Retatrutide 2mg?

Intex Pharma Retatrutide 2mg is pharmaceutical grade Retatrutide (LY3437943) supplied as 2mg of lyophilised powder in a vial for subcutaneous injection following reconstitution with bacteriostatic water. Retatrutide is the world’s most advanced triple hormone receptor agonist, simultaneously activating GLP-1, GIP and glucagon receptors to reduce appetite, improve metabolic health and raise energy expenditure. The vial format gives users full control over dose titration, making it the preferred choice for those starting at very low doses or managing protocols that require flexibility. Available from the Intex Pharma shop at £125.00 with same day UK despatch.

For users who prefer a no-preparation, pre-measured format, the Intex Pharma Retatrutide Prefilled Pen at £155.00 is also available. Both formats contain the same pharmaceutical grade Retatrutide verified by Janoshik Analytical before despatch.

How Retatrutide 2mg works

Retatrutide activates three distinct hormone receptors through a single molecule, producing layered weight loss effects that no single or dual agonist can replicate. Its six-day half-life supports once-weekly subcutaneous injection with steady plasma concentrations maintained between doses.

Clinical evidence

The Phase 2 randomised controlled trial published in the New England Journal of Medicine enrolled 338 adults with obesity and no type 2 diabetes over 48 weeks. Retatrutide at 12mg produced mean weight loss of 24.2% and at 8mg produced 22.8%. Every participant receiving 12mg lost at least 5% of body weight. Among this group, 83% achieved at least 15% weight loss. These are the largest reductions recorded in a Phase 2 obesity pharmacotherapy trial.

Phase 3 TRIUMPH-4 results announced by Eli Lilly in December 2025 reported average weight loss of 71.2 lbs alongside significant relief from osteoarthritis pain, confirming that the Phase 2 efficacy signal translates to large-scale Phase 3 populations.

How to reconstitute Intex Pharma Retatrutide 2mg

Retatrutide 2mg must be reconstituted with bacteriostatic water before injection. Do not use plain sterile water. Bacteriostatic water contains benzyl alcohol which preserves the peptide for up to 30 days refrigerated.

Dose reference at 1mg per ml concentration

Dosing protocol

The Retatrutide 2mg vial format is particularly suited to users who want to start at very low doses such as 0.25mg or 0.5mg per week and escalate gradually based on response. The standard titration protocol begins at 1mg weekly and escalates through 2mg, 4mg and then to maintenance doses. At 1mg per ml reconstitution, one 2mg vial provides exactly two weekly doses at the 1mg starting level or four doses at 0.5mg for users who prefer a slower initial titration.

Inject subcutaneously once weekly into the abdomen, thigh or upper arm. Rotate injection sites weekly. Use a 29 or 30 gauge insulin syringe for comfortable subcutaneous administration. Many UK users report significant appetite suppression and early weight loss at doses of 1 to 2mg per week without needing to escalate further, particularly in the first two to three months of treatment.

Side effects

• Nausea. Most common during dose escalation. Eating smaller, lower-fat meals and not eating immediately before the weekly injection reduces this significantly.
• Reduced appetite. The intended effect of the compound. Ensuring adequate protein, hydration and micronutrient intake is important during significant appetite suppression.
• Vomiting and diarrhoea. More common with rapid dose escalation. Spending at least four weeks at each dose level before moving higher substantially reduces gastrointestinal side effects.
• Fatigue. Reported in the early weeks of treatment. Typically resolves as the body adapts to the new metabolic environment.
• Injection site reactions. Mild redness or tenderness at the injection site. Rotating sites and injecting slowly with a fine gauge needle minimises this.

Retatrutide should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, in line with the precautionary labelling applied to all GLP-1 receptor agonist class compounds.

Frequently asked questions about Intex Pharma Retatrutide 2mg